Mitotically active cellular fibroma of the ovary: a rare case and review of literature

Figures & data

Figure 1: Intraoperative image showing a left pelvic mass adherent to the iliac vessels.

Figure 2: Microscopic appearance of mitotically active cellular fibroma.

Table 1: Patient characteristics

	Name and year of report	Age	Presenting symptoms		Findings	Mitotic count	Nuclear atypia	Ki-67	Necrosis	Haemorrhage	Rupture	Adhe rence	Surgery	CT/RT/HT	Outcome
1	Kaku et al..^6 (2007)	32		Abdominal pain	Left ovarian mass: 6.6 cm	17	Little	Strong	No	No	NM	NM	USO	No	12 months – DF
2	Bucella et al..^5 (2009)	65		Pelvic pain	12 cm mass in POD post THBSO for ovarian fibroma (10 cm) 5 years back	4	Bland	9%	No	NM	Yes	No	Incomplete resection (laparoscopic)	HT (tamoxifen)	Recurrence at 6 months – 8 cm in pararectal region – resection. – 6 months – DF
3	Monteiro et al..^3 (2012)	13		Amenorrhoea, abdominal distension, shortness of breath	19 cm mass – right ovary, Meig’s syndrome +	5–7	NS	NM	NM	NM	NM	No	USO + omentectomy	No	36 months – DF
4	Zong et al..^7 (2014)	39		Amenorrhoea, abdominal pain	11 cm mass in left adnexa	3–5	Mild	10%	No	No	Yes	Yes	THBSO + PLND + omentectomy + appendicectomy	No	66 months – DF
5	Wu et al.^8 (2014)	76		Mass per abdomen	NM	5–9	Bland	10%	NM	NM	NM	NM	THBSO	No	NM
6	Yamada et al.^9 (2015)	36		Incidental finding	6 cm right ovarian mass	10	NS	8.7%	No	No	No	No	USO	No	6 months – DF
7	Yildirim et al.^10 (2015)	24		Mass per abdomen	15 cm left adnexal mass	4	No	8%	Yes	NM	Yes	Yes	Cystectomy	No	DF
8	Current case	54		Lower limb oedema	9.5 cm left adnexal mass	6–8	Minimal	10%	No	NM	Yes	Yes	Resection + omentectomy	RT	24 months – DF

CT: chemotherapy, RT: radiation therapy, HT: hormonal therapy, POD: Pouch of Douglas, USO: unilateral salpingoophorectomy, THBSO: total hysterectomy with bilateral salpingoophorectomy, PLND: pelvic lymph node dissection, NM: not mentioned, NS: not significant DF: disease free.

Kaku S, Takeshima N, Akiyama F, Furuta R, Hirai Y, Takizawa K. A unique fibrous tumor of the ovary: fibrosarcoma or mitotically active cellular fibroma? Anticancer Res. 2007;27: 4365–4369.

 PubMed Web of Science ®Google Scholar

Bucella D, Limbosch JF, Buxant F, Simon P, Fayt I, Anaf V, et al. Recurrence of mitotically active cellular fibroma of the ovary. Obstet Gynecol Int. 2009;2009: 803062.

 PubMedGoogle Scholar

Monteiro SB, Costa A, Paiva V. Mitotically active cellular ovarian fibroma with Meigs’ syndrome and elevated CA-125: towards fertility preservation. J Pediatr Adolesc Gynecol. 2012;25: e107–109.10.1016/j.jpag.2012.05.012

 PubMedGoogle Scholar

Zong L, Lin M, Fan X. Mitotically active cellular fibroma of ovary should be differentiated from fibrosarcoma: a case report and review of literature. Int J Clin Exp Pathol. 2014;7: 7578–7582.

 PubMed Web of Science ®Google Scholar

Wu H, Xie J, Huang W, Wu J. Mitotically active cellular fibroma of the ovary: a case report and a review of the literature. Eur J Gynaecol Oncol. 2014;35: 81–83.

 PubMed Web of Science ®Google Scholar

Yamada T, Hattori K, Satomi H, Hirose Y, Nakai G, Daimon A, et al. Mitotically active cellular fibroma of the ovary: a case report and literature review. J Ovarian Res 2015;8: 65.10.1186/s13048-015-0191-x

 PubMed Web of Science ®Google Scholar

Yildirim N, Clock B, Akalin F, Gynecology C, Obuz H. Ugur. Mitotically active cellular fibroma of the ovary: a case report. J Turk Soc Obstet Gynecol 2015;1: 53–55.10.4274/tjod

 Google Scholar